EUVIMEDEUVIMED entdecken
Open Access

State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization

Kelly E Anderson, Nathorn Chaiyakunapruk, Eric J Gutierrez, H Weston Schmutz, Michael R Rose, Diana Brixner, R Brett McQueen

Health Affairs · 2024

DOI: 10.1377/hlthaff.2024.00118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs, 2024. Verfasst von Kelly E Anderson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kelly E. Anderson (Kelly.E.Anderson@cuanschutz.edu), University of Colorado Anschutz Medical Campus, Aurora, Colorado. Hauptthemen laut MEDLINE: Insulin, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Health Expenditures. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nearly all patients with type 1 diabetes and 20-30 percent of patients with type 2 diabetes use insulin to manage glycemic control. Approximately one-quarter of patients who use insulin report underuse because of cost. In response, more than twenty states have implemented monthly caps on insulin out-of-pocket spending, ranging from $25 to $100. Using a difference-in-differences approach, this study evaluated whether state-level caps on insulin out-of-pocket spending change insulin usage among commercially insured enrollees. The study included 33,134 people ages 18-64 who had type 1 diabetes or who used insulin to manage type 2 diabetes with commercial insurance coverage that was subject to state-level oversight and was included in the 25 percent sample of the IQVIA PharMetrics database during 2018-21. Insulin out-of-pocket caps did not significantly increase quarterly insulin claims for enrollees who had type 1 diabetes or who used insulin to manage type 2 diabetes. State-level caps on insulin out-of-pocket spending for commercial enrollees did not significantly increase insulin use; that may be in part because of out-of-pocket expenses being lower than cap amounts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Health ExpendituresHypoglycemic AgentsHumansFemaleMiddle AgedAdultMaleUnited StatesAdolescentInsurance Claim ReviewInsurance CoverageYoung AdultInsurance, HealthDrug Costs

Substanzen

InsulinHypoglycemic Agents

Autor:innen und Institutionen

  • Kelly E. Anderson (Kelly.E.Anderson@cuanschutz.edu), University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Nathorn Chaiyakunapruk, University of Utah, Salt Lake City, Utah.
  • Eric J. Gutierrez, University of Colorado Anschutz Medical Campus.
  • H. Weston Schmutz, University of Utah.
  • Michael R. Rose, Johns Hopkins University, Baltimore, Maryland.
  • Diana Brixner, University of Utah.

Förderung

  • AHRQ HHS
  • NCATS NIH HHS

Zitieren

APA

Anderson, K. E., Chaiyakunapruk, N., Gutierrez, E. J., Schmutz, H. W., Rose, M. R., Brixner, D., & McQueen, R. B. (2024). State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization. Health Affairs. https://doi.org/10.1377/hlthaff.2024.00118

Vancouver

Anderson KE, Chaiyakunapruk N, Gutierrez EJ, Schmutz HW, Rose MR, Brixner D, et al. State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization. Health Affairs. 2024. doi:10.1377/hlthaff.2024.00118

BibTeX
@article{Anderson2024,
  author = {Anderson, Kelly E and Chaiyakunapruk, Nathorn and Gutierrez, Eric J and Schmutz, H Weston and Rose, Michael R and Brixner, Diana and McQueen, R Brett},
  title = {State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization},
  journal = {Health Affairs},
  year = {2024},
  doi = {10.1377/hlthaff.2024.00118}
}
Kostenlos starten →